Silence Therapeutics (SLNCF)

[gfp927z]

>>> AtuRNAi

Silence Therapeutics has developed novel proprietary siRNA, which has been chemically modified to result in a blunt-ended, chemically stabilized molecule (see figure 1), which contains only naturally-occurring RNA.

Key advantages include:

Stability against nuclease degradation (figure 2) resulting in longer half-life, lower doses and less frequent administration

Elimination of toxic metabolites as a result of only naturally occurring building blocks

Lower manufacturing costs through cheaper building blocks

Increased yield and faster synthesis through improved process development.



AtuPlex / AtuFect

Improving systemic siRNA delivery to target cells, Silence Therapeutics has developed a proprietary liposomal delivery system (also known as lipoplex technology) called AtuPLEX. AtuPLEX contains proprietary lipid components called AtuFECT.

AtuPLEX has been shown to:

Increase functional intracellular uptake (endosomal release) of siRNA compared with ‘naked’ delivery.


Increase bioavailability and circulation time


Increase systemic delivery to endothelium, liver, tumours and other tissues

AtuPLEX technology is ideal for the development of anti-angiogenic/anti-vascular therapies for solid cancer and cardiovascular diseases. <<<